Neuroendocrine Tumors  >>  Signifor LAR (pasireotide long acting release)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Signifor LAR (pasireotide long acting release) / Recordati
COOPERATE-1, NCT01374451 / 2010-023183-40: Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

Terminated
2
160
Japan, US, Canada, Europe, RoW
Everolimus, RAD001, Pasireotide LAR, SOM230 LAR
Novartis Pharmaceuticals
Islet Cell Tumor
02/15
02/15
NCT00958841 / 2008-007348-32: Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Terminated
2
118
US, Canada, Europe, RoW
pasireotide LAR, SOM230
Novartis Pharmaceuticals
Pancreatic Neoplasm, Pituitary Neoplasm, Nelson Syndrome, Ectopic ACTH Syndrome
06/15
06/15
NCT02021942 / 2010-019017-25: Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size

Completed
2
16
Europe
SOM230 LAR, Pasireotide, Sandostatin®
Prof. Dr. Berthold Schalke, Crolll Gmbh
Primary Inoperable Thymoma, Local Recurrent Thymoma
10/15
10/15

Download Options